Emergent BioSolutions gets $75M BARDA contract option for CYFENDUS anthrax vaccine

Emergent BioSolutions Inc.

BARDA exercised a $75 million option under contract HHSO100201600030C for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).
Deliveries begin in 2023 and are expected to be complete by end of Q1 2024.
CYFENDUS was approved by FDA in July 2023 as a two-dose post-exposure prophylaxis for ages 18+.
The vaccine supports U.S. anthrax preparedness strategy and is part of Emergent's medical countermeasures franchise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.